1. Marmot J. The attractiveness of France for the healthcare industry [L'attractivité de la France pour les industries des biens de santé]. Ministère de l'industrie; 2004 [Last accessed 7 April 2015]. Available from: http://www.ladocumentationfrancaise.fr/rapports-publics/044000208/index.shtml .
2. Masson A. Following the example of other country's public policies to improve the attractiveness for the innovative pharmaceutical industry [S'inspirer des politiques publiques étrangères d'attractivité pour l'industrie pharmaceutique innovante]. Conseil général des mines; 2004 [Last accessed 7 April 2015]. Available from: http://www.ladocumentationfrancaise.fr/rapports-publics/044000206/index.shtml .
3. LEEM. The attractiveness of France for International clinical research. 2006 [Last accessed 7 April 2015]. Available from: http://www.ariis.fr/2007/05/29/attractivite-de-la-france-pour-la-recherche-clinique/ .
4. Zannad F, Pletan Y. Difficulties with conducting clinical trials in France. Therapie. 2001;56(4):341–7.
5. European Parliament and Council. Directive 2001/20/EC of the European Parliament and the Council of 4 Apr 2001 on the approximation of laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. In. Edited by Community OJE, vol. L121:34–44; 2001.